Sight Sciences Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Sight Sciences Inc's ROI in the second quarter of 2026?
Sight Sciences Inc recorded a cumulative net loss of $-30 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -30.95%.

Within the Healthcare sector 373 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 3594, from total ROI ranking in the first quarter of 2026 at 4166.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-20.66 %	-19.74 %	-18.82 %	-18.62 %	-18.8 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	84	92	104	104	110
Return On Investment (TTM)	-30.95 %	-36.32 %	-35.23 %	-40.15 %	-40.44 %
SGHT's Overall Ranking	# 3594	# 4166	# 3747	# 3771	# 3785
Seq. Investment Change TTM	-6.25 %	-5.96 %	-5.03 %	-5.23 %	-5.16 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-30	-37	-38	-46	-49

SGHT Company Profile >> Back to SGHT Roi Comparisons >> See Annual SGHT Return On Investment

Return On Investment SGHT's Ranking
Within:	No.
Industry	# 110
Sector	# 374
Overall	# 3594

Return On Investment Statistics
High	Average	Low
-30.95 %	-75.18 %	-596.58 %
(Jun 30 2026)		(Dec 31 2021)

News about Sight Sciences Inc Return on Investment ROI

Vision on the Brink: Sight Sciences Leadership Shuffle Amid Financial Headwinds

November 7, 2024

In a notable shift aimed at reinvigorating its strategic direction, Sight Sciences Inc. has recently appointed MK Raheja as Executive Vice President of Research and Development, and Brenton Taylor as Executive Vice President of Operations. These appointments signal the company’s renewed commitment to innovating in the eyecare landscape, particularly in light of the staggering financial challenges it currently faces.Navigating Financial ChallengesSight Sciences has reported a cumulative net loss of $52 million for the 12 months concluding in the second quarter of 2024. This is compounded by a negative return on investment (ROI) of -35.06%. Such financial data raises alarms about the company’s sustainability and ability to invest in long-term growth initiatives. These figures paint a stark picture: while the commitment to advancing eyecare solutions is clear, the financial foundation on which these ambitions rest appears shaky.

Evaluating the Clinical Efficacy of TearCare Treatment for Dry Eye Disease Amidst the Financial Landscape of Sight Sc...

October 14, 2024

Dry eye disease (DED) remains a significant public health concern, impacting the quality of life of individuals globally. Recent advancements in treatment options, particularly investigator-initiated clinical trials involving TearCare, present a promising outlook for enhanced patient outcomes. However, these clinical successes occur against a backdrop of ongoing financial challenges for companies like Sight Sciences Inc. which is navigating substantial net losses and lower returns on investment (ROI). This article aims to balance the clinical advancements against the financial realities faced by companies developing these innovative therapies. Clinical Findings: TearCare Treatment for Dry Eye Disease The recent study evaluating the impact of TearCare treatment on patients with dry eye disease demonstrated significant improvements in key functional visual metrics. The intervention led to enhanced reading speed and an overall better quality of life related to vision, underscoring the potential benefits of a strategic, interventional approach to managing DED.

Financial Statements
Sight Sciences Inc's II. Quarter Investments	$ 84 Millions	SGHT's Balance sheet
Sight Sciences Inc's II. Quarter Income	$ -4 Millions	Quarterly SGHT's Income Statement
SGHT's Income by Division		See SGHT's Income by Division

SGHT Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	104	127	154	195	267
Y / Y Investment Growth	-18.13 %	-17.51 %	-20.92 %	-26.78 %	-
Net Income in Millions	-38	-52	-56	-86	-63
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-36.85 %	-40.44 %	-35.98 %	-44.17 %	-23.61 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SGHT's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SGHT's Competitors
Subscribers only: Roi for Sight Sciences Inc's Suppliers
Subscribers only: Return On Investment for SGHT's Customers

Other Ratios
SGHT's Roa	SGHT's Inventory Turnover Ratio	SGHT's Growth Rates	SGHT's Dividend Statistics
	SGHT's Profitability Ratios	SGHT's Asset Turnover Ratio	SGHT's Dividend Growth
SGHT's Roe	SGHT's Valuation Ratios	SGHT's Financial Strength Ratios	SGHT's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-11T09:54:33+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.